Catheter Precision, Inc. Secures up to $36.5 Million in Strategic Institutional Financing to Accelerate Growth

Catheter Precision (NYSE: VTAK) agreed to terminate its at-the-market equity offering and completed a strategic institutional financing for up to $36.5 million to accelerate growth.

Rhea-AI Summary

Catheter Precision (NYSE: VTAK) agreed to terminate its at-the-market equity offering and completed a strategic institutional financing for up to $36.5 million to accelerate growth. The company converted approximately $9 million of short and long-term liabilities into equity and extended note maturities to two and three years, strengthening liquidity and aligning with long-term investors.

The company said no future equity lines or forward-priced agreements are anticipated; additional transaction details are available in its Form 8-K filings.

Positive

• $36.5M institutional financing secured
• Approximately $9M liabilities converted into equity
• Extended note maturities to 2–3 years
• ATM equity program terminated; no future equity lines anticipated

Negative

• Conversion into equity may cause shareholder dilution
• Press release omits pricing and specific transaction terms

Argus Feb 12 session

-33.16% close to close 67.5x rel. volume Open Argus

Details

News Market Reaction – VTAK

On Feb 12, the day this news came out, VTAK closed 33.16% below the previous close. That session’s volume was 67.5x the stock’s average daily volume.

Data tracked by StockTitan Argus for the Feb 12 session.

Key Figures

Strategic financing size: $36.5 million Liabilities converted: approximately $9 million Private placement gross proceeds: $2,177,759.00 +5 more

Strategic financing size

$36.5 million

Institutional financing capacity referenced in Feb 12, 2026 release

Liabilities converted

approximately $9 million

Additional short and long-term liabilities on 9/30/25 balance sheet converted to equity

Private placement gross proceeds

$2,177,759.00

Initial closing from Feb 6, 2026 8‑K private placement

Optional Series C-4 capacity

$39,233,333

Investor option to buy additional Series C-4 preferred per Feb 6, 2026 8‑K

Fly Flyte stake value

$5.25 million

Value of 19.98% Fly Flyte, Inc. stake in Feb 6, 2026 8‑K

Q3 2025 revenue

$226,000

Quarter ended September 30, 2025 from 10‑Q

Q3 2025 net loss

$2.251 million

Net loss attributable to company in Q3 2025 10‑Q

Cash balance

$1.075 million

Cash and cash equivalents as of September 30, 2025 per 10‑Q

Historical Context

5 past events · Latest: Feb 05

5 events

1. Feb 05

   Product visibility

   24h Move

   -4.8%

   LockeT device featured in live procedural cases at a major conference.

2. Feb 04

   Commercial update

   24h Move

   +1.6%

   Expanded hospital approvals and highest January revenue for LockeT.

3. Jan 22

   International expansion

   24h Move

   +10.4%

   First LockeT purchase order in Germany, entering a large EP devices market.

4. Jan 20

   Global footprint

   24h Move

   -1.9%

   New VIVO order in Slovenia, expanding commercial reach to 15 countries.

5. Dec 18

   European expansion

   24h Move

   +0.9%

   Multi‑year LockeT commitment at a major Irish EP center, eighth EU country.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

at-the-market equity offering program, atm equity offering, form 8-k, schedule 13g, +4 more

8 terms

at-the-market equity offering program financial

"agreed to the termination of its at-the-market (“ATM”) equity offering program"

A program that lets a company sell newly issued shares directly into the open market at whatever the current trading price is, usually through a broker, and do so gradually over time instead of all at once. Investors care because it can dilute existing ownership and put steady selling pressure on the stock price, while giving the company a flexible, on-demand way to raise cash — like adding small amounts of water to a pool rather than dumping in a bucket.

atm equity offering financial

"termination of its at-the-market (“ATM”) equity offering program"

An at-the-market (ATM) equity offering is a way for a company to sell newly issued shares directly into the open market over time at prevailing prices instead of in one large sale. Think of it like a baker selling individual slices throughout the day at the store’s current price; it gives the company flexible, on-demand access to cash but can dilute existing shareholders and put downward pressure on the stock if many shares are issued.

form 8-k regulatory

"Please refer to the Company’s Current Report on Form 8-K filed February 6, 2026"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

schedule 13g regulatory

"Catheter Precision, Inc. (VTAK) received a Schedule 13G filing"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

convertible preferred stock financial

"multiple new series of convertible preferred stock to raise capital"

Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.

registration rights agreement regulatory

"A registration rights agreement requires Catheter Precision to register resales"

A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.

reverse stock split financial

"A 1‑for‑19 reverse stock split became effective on August 15, 2025"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

going concern financial

"Management states there is substantial doubt about the ability to continue as a going concern"

Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

VTAK has Agreed to Terminate its At-The-Market (“ATM”) Equity Offering Program

Company Strengthens Balance Sheet and Aligns Institutional Capital for Long-Term Value Creation

FORT MILL, S.C., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) (“Catheter Precision” or the “Company”), a leader in advanced electrophysiology solutions, today announced that it has agreed to the termination of its at-the-market (“ATM”) equity offering program and has completed a strategic financing transaction with institutional investors for up to $36.5 million to support accelerated growth.

Key Highlights:

• ATM equity program to be terminated. No future equity lines of credit or forward-priced agreements are anticipated.
• Strategic institutional capital secured to fund expansion
• Balance sheet and liquidity significantly strengthened
• The company’s short-term notes have been converted to long term by extending maturities out to two and three years
• Additional short and long-term liabilities of approximately $9 million on the 9/30/25 balance sheet are being converted into equity
  
  

Executive Commentary
“This financing and balance sheet restructuring strengthens our financial position and also reinforces institutional investor confidence in our strategy,” said David Jenkins, CEO and Chairman of VTAK.

Jenkins added, “By eliminating legacy financing overhang and aligning ourselves with long-term institutional partners, we’ve enhanced our ability to execute with speed, discipline, and focus.”

Jenkins concluded, “We now move forward from a position of financial strength, supported by capital, stability, and strategic alignment to drive meaningful shareholder value through disciplined growth.”

Capital Strategy Update
This strategic institutional investment provides the Company with financial flexibility to:

• Advance key growth initiatives
• Scale multiple business opportunities
• Expand market presence and execution capabilities
  
  

Additional Information
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Please refer to the Company’s Current Report on Form 8-K filed February 6, 2026, and February 12th for additional details regarding the transaction.

About Catheter Precision
Catheter Precision is a U.S.-based medical device company developing innovative solutions to improve the treatment of cardiac arrhythmias. The Company is committed to bringing new technologies to market through physician collaboration and continued product innovation.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to risks and uncertainties described in the Company’s SEC filings, available at www.sec.gov. The Company undertakes no obligation to update these statements except as required by law.

CONTACTS:

Investor Relations
973-691-2000
IR@catheterprecision.com

# # #

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What financing did Catheter Precision (VTAK) announce on February 12, 2026?

Catheter Precision announced a strategic institutional financing of up to $36.5 million. According to the company, the funding supports growth initiatives and strengthens liquidity while aligning with long-term institutional investors.

How did the February 12, 2026 financing affect VTAK's balance sheet?

The financing strengthened VTAK's balance sheet by converting liabilities into equity and extending notes. According to the company, about $9 million of short and long-term liabilities were converted to equity and maturities extended to two and three years.

What change did Catheter Precision make to its ATM program on February 12, 2026?

Catheter Precision terminated its at-the-market (ATM) equity offering program and expects no future equity lines. According to the company, this removes legacy financing overhang and aligns capital with long-term institutional partners.

Will the VTAK financing cause shareholder dilution?

The transaction includes conversion of liabilities into equity, which can dilute existing shareholders. According to the company, approximately $9 million of liabilities were converted to equity, though exact dilution percentages were not disclosed.

Where can investors find more details about the VTAK financing transaction?

Investors should review the company's Form 8-K filings filed February 6 and February 12, 2026 for details. According to the company, those filings contain additional transaction terms and disclosures not included in the press release.